In the current AD diagnostic criteria, cerebrospinal fluid (CSF), namely, CSF amyloid β 42 (Aβ 42) or Aβ 42/40, phosphorylated tau and total tau levels and/or PET biomarkers, i.e., amyloid PET and tau PET, were included [37,38]. This evidence concerns the gene MAPT and Alzheimer disease.